混合抗原受体T细胞疗法在伴有继发中枢神经系统侵犯的曼特尔细胞淋巴瘤中的临床疗效和安全性。
Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement.
发表日期：2023 Aug 16
作者：
Christine E Ryan, Rebecca L Zon, Robert Redd, David C Fisher, Roni Shouval, Anita Kumar, Jennifer L Crombie, Hossein Sadrzadeh, Austin I Kim, Lakshmi Nayak, Ugonma N Chukwueke, Caron A Jacobson, Matthew J Frigault, M Lia Palomba, Philippe Armand, Zachary Epstein-Peterson, Reid W Merryman
来源：
BRITISH JOURNAL OF HAEMATOLOGY
摘要：
关于具有淋巴滤泡携带细胞淋巴瘤（MCL）并发次级中枢神经系统（SCNS）受累的嵌合抗原受体（CAR）T细胞治疗结果的数据有限。我们在美国三所学术中心识别了10例MCL并伴有SCNS受累的患者，接受了抗CD19 CAR T细胞治疗。在中枢神经系统（86%）和全身（90%）观察到了频繁的客观反应，1年无进展生存率为47%。7例患者发生了免疫效应细胞相关的神经毒性综合征（n = 2级别1，n = 5级别3）。我们的结果表明，在这种情况下，抗CD19 CAR T细胞治疗是可行的，并且可能需要进一步的关于该人群神经毒性的数据。©2023 British Society for Haematology and John Wiley & Sons Ltd.
Data describing outcomes of chimeric antigen receptor (CAR) T-cell therapy in patients with secondary central nervous system (SCNS) involvement of mantle cell lymphoma (MCL) are limited. We identified 10 patients with MCL and SCNS involvement treated with anti-CD19 CAR T-cell therapy at three US academic centres. Frequent objective responses were observed in the CNS (86%) and systemically (90%), and the 1-year progression-free survival was 47%. Seven patients developed immune-effector-cell-associated-neurotoxicity-syndrome (n = 2 Grade 1, n = 5 Grade 3). Our results suggest that anti-CD19 CAR T-cell therapy in this setting is feasible and additional data regarding neurotoxicity in this population may be warranted.© 2023 British Society for Haematology and John Wiley & Sons Ltd.